Active substance
Dexamfetamine
- US FDA 41
- Health Canada 7
- US price lines 15
- NHS prices 4
- Safety 12
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DEXEDRINE SPANSULE | 5MG; 10MG; 15MG | capsule, extended release · oral | IMPAX LABS INC | Prescription | 2 Aug 1976 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | BARR | Prescription | 31 Jan 2001 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | SPECGX LLC | Prescription | 29 Jan 2002 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG; 15MG | capsule, extended release · oral | SPECGX LLC | Prescription | 6 May 2003 |
| DEXTROAMPHETAMINE SULFATE | 5MG/5ML | solution · oral | PRASCO | Prescription | 29 Jan 2008 |
| DEXTROAMPHETAMINE SULFATE | 2.5MG; 5MG; 7.5MG; 10MG; 15MG; 20MG; 30MG | tablet · oral | AZURITY | Prescription | 25 Oct 2011 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG; 15MG | capsule, extended release · oral | ACTAVIS ELIZABETH | Prescription | 30 Nov 2012 |
| DEXTROAMPHETAMINE SULFATE | 5MG/5ML | solution · oral | TRIS PHARMA INC | Prescription | 29 May 2013 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | AUROLIFE PHARMA LLC | Prescription | 31 Jul 2013 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | AVANTHI INC | Prescription | 23 Nov 2015 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | NOVEL LABS INC | Prescription | 16 Mar 2016 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | NUVO PHARM | Prescription | 18 Oct 2017 |
| DEXTROAMPHETAMINE SULFATE | 2.5MG; 5MG; 7.5MG; 10MG; 15MG; 20MG; 30MG | tablet · oral | WINDER LABS LLC | Prescription | 7 Jun 2021 |
| XELSTRYM | 4.5MG/9HR; 9MG/9HR; 13.5MG/9HR; 18MG/9HR | system · transdermal | NOVEN PHARMS INC | Prescription | 22 Mar 2022 |
| DEXTROSTAT | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | SHIRE | Discontinued | 29 May 1975 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG | tablet · oral | LANNETT | Discontinued | 29 Oct 1975 |
| DEXEDRINE | 5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | elixir · oral | GLAXOSMITHKLINE | Discontinued | 26 Feb 1976 |
| DEXEDRINE | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | GLAXOSMITHKLINE | Discontinued | 26 Feb 1976 |
| FERNDEX | 5MG | tablet · oral | FERNDALE LABS | Discontinued | 15 Jun 1977 |
| DEXTROAMPHETAMINE SULFATE | 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | LANNETT | Discontinued | 20 Jun 1980 |
| DEXTROAMPHETAMINE SULFATE | 5MG | tablet · oral | STRIDES PHARMA INTL | Discontinued | 13 May 1999 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG; 15MG | capsule, extended release · oral | PHARMAZONE | Discontinued | 18 Jan 2002 |
| DEXTROAMPHETAMINE SULFATE | 5MG | tablet · oral | NESHER PHARMS | Discontinued | 31 Oct 2002 |
| DEXTROAMPHETAMINE SULFATE | 10MG | tablet · oral | NESHER PHARMS | Discontinued | 31 Oct 2002 |
| DEXTROAMPHETAMINE SULFATE | 5MG; 10MG; 15MG | capsule, extended release · oral | ABLE | Discontinued | 25 Aug 2004 |
16 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DEXEDRINE | 01924516 | 5 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| DEXEDRINE SPANSULE | 01924559 | 10 MG | CAPSULE (SUSTAINED-RELEASE) · ORAL | KNIGHT THERAPEUTICS INC. |
| DEXEDRINE SPANSULE | 01924567 | 15 MG | CAPSULE (SUSTAINED-RELEASE) · ORAL | KNIGHT THERAPEUTICS INC. |
| DEXTROAMPHETAMINE | 02443236 | 5 MG | TABLET · ORAL | AA PHARMA INC |
| PMS-DEXTROAMPHETAMINE | 02566605 | 5 MG | TABLET · ORAL | PHARMASCIENCE INC |
| TEVA-DEXTROAMPHETAMINE SR | 02448319 | 10 MG | CAPSULE (SUSTAINED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| TEVA-DEXTROAMPHETAMINE SR | 02448327 | 15 MG | CAPSULE (SUSTAINED-RELEASE) · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DEXTROAMPHETAMINE 10 MG TAB | $0.37325 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 15 MG TAB | $5.4497 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 2.5 MG TAB | $3.95113 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 20 MG TAB | $5.41457 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 30 MG TAB | $5.48996 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 5 MG TAB | $0.38361 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 5 MG/5 ML | $1.14342 | per ML | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE 7.5 MG TAB | $5.83093 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE ER 10 MG CAP | $1.05126 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE ER 15 MG CAP | $1.33772 | per EA | 23 Sep 2026 |
| US NADAC | DEXTROAMPHETAMINE ER 5 MG CAP | $1.10063 | per EA | 23 Sep 2026 |
| US NADAC | XELSTRYM 13.5 MG/9 HR PATCH | $16.25846 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Dexamfetamine 10mg tablets | £39.78 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Dexamfetamine 20mg tablets | £79.56 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Dexamfetamine 5mg tablets | £19.85 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Dexamfetamine 5mg/5ml oral solution sugar free | £190.66 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 23 Apr 2026 ADDERALL XR 10 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Apr 2026 MYDAYIS — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Sep 2025 XELSTRYM — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Sep 2025 DEXEDRINE SPANSULE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 10 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 12.5 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 15 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 20 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 30 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 5 — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 ADDERALL 7.5 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2023 DEXEDRINE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.